Healthcare & Pharma
M&A Database
In the Healthcare & Pharma sector, the average EBITDA multiple recorded since the beginning of the year is 13.4x, which represents a 3.3% decrease compared to 2025.
Sign up for free to unlock financial data on each deal including Enterprise Value and transaction multiples (xRevenue, xEBITDA, xEBIT).
Database
300 Deals in Healthcare & Pharma
| Date | Target | Acquirer | Sector | Rev | EBITDA | EV | xRev | xEBITDA |
|---|---|---|---|---|---|---|---|---|
| 12/2021 | VIVALTO SANTÉ FRANCE | VIVALTO PARTNERS | Healthcare Facilities | XX.X | X.X | XXX | X.Xx | X.Xx |
| 11/2021 | LABEXA FRANCE | CERBA HEALTHCARE | Healthcare Facilities | XX.X | X.X | XXX | X.Xx | X.Xx |
| 11/2021 | ATOS MEDICAL SWEDEN | COLOPLAST | Medical Devices | XX.X | X.X | XXX | X.Xx | X.Xx |
| 10/2021 | POINT VISION FRANCE | ARES | Outpatient Care | XX.X | X.X | XXX | X.Xx | X.Xx |
| 10/2021 | VETONE FRANCE | IVC EVIDENSIA | Outpatient Care | XX.X | X.X | XXX | X.Xx | X.Xx |
| 09/2021 | HRA PHARMA FRANCE | PERRIGO COMPANY | Pharma & Biotech | XX.X | X.X | XXX | X.Xx | X.Xx |
| 09/2021 | EVERLIGHT RADIOLOGY UNITED KINGDOM | LIVINGBRIDGE | Outpatient Care | XX.X | X.X | XXX | X.Xx | X.Xx |
| 08/2021 | CURAEOS NETHERLANDS | COLOSSEUM DENTAL GROUP | Outpatient Care | XX.X | X.X | XXX | X.Xx | X.Xx |
| 07/2021 | BLIKK GROUP GERMANY | EQT PARTNERS | Outpatient Care | XX.X | X.X | XXX | X.Xx | X.Xx |
| 07/2021 | ALMAVIVA SANTÉ FRANCE | WREN HOUSE | Healthcare Facilities | XX.X | X.X | XXX | X.Xx | X.Xx |
| 07/2021 | AMEDES GERMANY | OMERS | Healthcare Facilities | XX.X | X.X | XXX | X.Xx | X.Xx |
| 07/2021 | PHARMATHEN GREECE | PARTNERS GROUP | Pharma & Biotech | XX.X | X.X | XXX | X.Xx | X.Xx |
| 07/2021 | INTECH MEDICAL FRANCE | MONTAGU PRIVATE EQUITY | Medical Devices | XX.X | X.X | XXX | X.Xx | X.Xx |
| 07/2021 | LIFEBRAIN ITALY | CERBA HEALTHCARE | Healthcare Facilities | XX.X | X.X | XXX | X.Xx | X.Xx |
| 07/2021 | MEINE RADIOLOGIE GERMANY | EQT PARTNERS | Outpatient Care | XX.X | X.X | XXX | X.Xx | X.Xx |
What does the Healthcare & Pharma M&A sector cover?
On mynth, the Healthcare & Pharma M&A sector is structured across 3 major verticals with Life Sciences, Health Providers, and Healthcare Services, covering 11 sub-sectors and 16 granular industry tags. This taxonomy mirrors how M&A professionals actually segment the market, enabling precise peer group construction and sector-specific EV/EBITDA benchmarking across European Small & Mid-Cap transactions.
What is the average EV/EBITDA multiple for Healthcare & Pharma transactions in 2026?
mynth tracks 300+ verified Healthcare & Pharma M&A transactions with an average EV/EBITDA of 13.4x for the year 2026. Our Healthcare & Pharma vertical provides deep granular data across the entire value chain of the Healthcare & Pharma industries. We track valuation multiples and transaction financials for a wide range of sub-industries, including Life Sciences, Animal Health, Medical Devices, Implants & Prosthetics, Diagnostic Equipment, Medical Consumables, Pharma & Biotech, CDMO, Generics / Labs and R&D Biotech. Whether you are looking for benchmarks in niche Healthcare & Pharma segments or broad market trends, mynth centralizes deal flow intelligence that covers specialized mid-market players and large-scale industrial consolidators across Europe. Our database is specifically designed to help analysts identify EBITDA multiples and Revenue trends within these highly regulated and capital-intensive sectors.
Who are the most active acquirers in European Healthcare & Pharma M&A?
According to mynth's community-contributed database of European Healthcare & Pharma transactions over the last 5 years, 62.9% of deals were driven by Private Equity firms while 37.1% were led by strategic acquirers. Among the most active buyers tracked on mynth: Ardian, a private equity firm based in FRANCE, with 17 transactions, Eqt Partners, a private equity firm based in SWEDEN, with 9 deals, Permira, a private equity firm based in UNITED KINGDOM, with 9 operations, Eurazeo, a private equity firm based in FRANCE, with 7 acquisitions, Ik Partners, a private equity firm based in UNITED KINGDOM, with 5 transactions. This breakdown reflects the consolidation dynamics of the European Healthcare & Pharma mid-market, where Private Equity firms have been particularly active in consolidating outpatient care, dental networks and veterinary clinics through buy-and-build strategies, while strategic acquirers focus on pharma and medtech bolt-on acquisitions.
How did we build this Healthcare & Pharma analysis?
The 13.4x average EV/EBITDA is based on mynth’s verified database of 300+ Healthcare & Pharma M&A transactions. The data is contributed by M&A and private equity professionals, then manually reviewed by mynth’s analysts to ensure consistency and accuracy. Each transaction is validated by comparing submitted figures with press releases, public announcements, market coverage, and private documents when available. This methodology gives mynth access to transaction-level intelligence that is often unavailable in traditional databases, allowing for a more precise view of valuation trends across the Healthcare & Pharma industry. Thanks to this community-driven approach, we provide a unique and highly granular view of each sector and sub-sector, from Life Sciences and Health Providers to Animal Health, Medical Devices and Pharma & Biotech, as examples.
How does mynth enrich this analysis for users?
Once logged in, users can access detailed financial data for each transaction, including the Enterprise Value, Equity Value, Revenue, EBITDA, and EBIT for the current year and for prior fiscal years, as well as the corresponding Revenue, EBITDA, and EBIT multiples. On each deal page, the sources of the financial data are clearly indicated: links to press articles or official announcements, or a tag specifying when the data comes from confidential documents shared by the user. This transparency helps users assess the reliability and origin of the valuation figures. Every company in the database is tagged by sector with four levels of granularity, enabling users to distinguish between very different business models and valuation approaches that would otherwise be hidden at a broad sector level. This granularity helps distinguish between clinical‑pipeline driven biotechs, capital‑heavy hospital chains, and asset‑light service providers, each with very different valuation profiles. The platform also tags each company by geography, enabling users to focus on specific countries or regions. mynth features a powerful search engine that lets you run highly refined queries by sector (with all four levels of industry depth), country, and company size, so you can quickly build custom peer groups, compare multiples, and export results directly to Excel.
What is mynth?
mynth is the first free M&A database dedicated to European Small & Mid-Cap transactions. We centralize Enterprise Values, revenue multiples, EBITDA multiples and transaction financials that are typically locked behind five-figure subscriptions on platforms like Capital IQ or Mergermarket. On mynth, searching and browsing deals is completely free. Our mission is simple: make professional-grade valuation intelligence accessible to every M&A advisor, independent consultant, Private Equity professional and student, without the burden of expensive annual licenses.
How to use mynth for free?
Sign up for free and instantly receive 30 credits. Through our referral program, each person you invite earns you an additional 20 credits, meaning you can unlock at least 50 financial data points without spending a cent. Our search engine is built for speed and precision: filter transactions by company name, investment fund, sector, country, revenue range, enterprise value or date. A list system lets you group transactions into custom peer groups and export them directly to Excel. The credit model means you only spend on the deals you actually need : no subscription, no commitment.
Powered by Collective Intelligence
mynth is a community-driven database. Every transaction is contributed by M&A and Private Equity professionals who work on the deals themselves. This means our database contains off-market financial data that you will not find in any press release, news article, or traditional data provider. Closed deals, undisclosed valuations, real EBITDA multiples : data that only exists within the deal teams. Every single financial figure submitted is reviewed and validated by our in-house analysts before being published, ensuring the data you see is accurate, structured, and reliable.